Hims & Hers stock steadies in premarket as Citi cuts target, SEC probe keeps GLP-1 risks in play

Hims & Hers Health shares nudged 0.3% higher ahead of Thursday’s open, building on Wednesday’s 2.3% advance. The telehealth firm wrapped up the last session at $15.82, after trading in a range from $15.06 to $16.46 during the day. On Tuesday, the stock had dropped to $13.74.

NASDAQ:HIMS · NYSE:NVO · Pharmaceutical Industry · Stock Market
Eli Lilly stock: what to watch Monday after FDA pressure forces Hims to pull a weight-loss pill

Eli Lilly stock: what to watch Monday after FDA pressure forces Hims to pull a weight-loss pill

Eli Lilly will take the spotlight Monday as Wall Street reopens, after Hims & Hers announced it’s pulling its compounded weight-loss pill in response to a U.S. Food and Drug Administration warning. Lilly's shares closed Friday at $1,058.18, rising 3.7%. “No one should be mass-compounding or selling knockoff GLP-1 products regardless of how they’re administered,” a Lilly spokesperson said.
8 February 2026
···
Eli Lilly stock rebounds after FDA flags copycat weight-loss drugs; what’s next for LLY

Eli Lilly stock rebounds after FDA flags copycat weight-loss drugs; what’s next for LLY

Eli Lilly and Company shares climbed about 3% on Friday, recovering part of Thursday’s steep 8% drop. The rebound came after the U.S. Food and Drug Administration indicated it would crack down on illegal copycat weight-loss drugs. The stock traded up 3% at $1,051.74. FDA Commissioner Marty Makary emphasized the agency cannot vouch for the “quality, safety or effectiveness” of these non-approved medicines.
6 February 2026
····
Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

Shares of Hims & Hers Health dropped 3.8% to $23.48 in premarket trading on Friday. The slide came after FDA Commissioner Marty Makary warned the agency would act quickly against firms mass-marketing “illegal copycat drugs.” The stock had already fallen 3.8% on Thursday and plunged nearly 10% after hours, following Makary’s post on X stating, “The FDA cannot verify the quality, safety, or effectiveness of non-approved drugs.” His comments came after Hims introduced a compounded version of Novo Nordisk’s Wegovy weight-loss medication.
6 February 2026
····
Novo Nordisk stock plunges as 2026 sales warning fuels price-war fears around Wegovy

Novo Nordisk stock plunges as 2026 sales warning fuels price-war fears around Wegovy

Shares of Novo Nordisk plunged roughly 16% in Copenhagen on Wednesday after the Wegovy maker warned that sales and profits could dip in 2026 amid renewed pressure on U.S. drug prices. Jyske Bank analysts described the revised outlook as “yet another blow” for investors. In New York, the company’s ADRs dropped $1.94, or about 3.9%, to $48.36.
4 February 2026
···
Novo Nordisk stock hammered as Ozempic maker warns 2026 sales may fall up to 13%

Novo Nordisk stock hammered as Ozempic maker warns 2026 sales may fall up to 13%

Novo Nordisk shares dropped sharply on Wednesday after the Danish pharmaceutical giant flagged a potential 13% decline in sales and profit for 2026, marking a notable reversal for the company behind weight-loss drug Wegovy and diabetes treatment Ozempic. Early trading in Copenhagen saw shares plunge 18%, according to the Financial Times. https://www.ft.com/content/d148ce25-fa76-468b-b9ac-95c62a994a55
4 February 2026
···
Eli Lilly stock price drops 4% as Novo outlook jars weight-loss trade ahead of earnings

Eli Lilly stock price drops 4% as Novo outlook jars weight-loss trade ahead of earnings

Eli Lilly and Company shares dropped 3.9%, closing at $1,003.46 on Tuesday, then held steady in after-hours trading. Novo Nordisk’s U.S.-listed shares plunged 14%, after it forecast a steeper sales decline than expected for 2026, weighing on the obesity-drug sector. Pfizer also slipped following new weight-loss drug data. “Novo’s showing there’s a market for oral options,” noted Citizens analyst Jonathan Wolleben.
4 February 2026
····
1 2 3 4 … 8
Follow on Google News
Add as preferred source Open in Google News